top of page
Dynamic Drug Advancement Limited | Durham Institute of Respirology
About the Trial
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Mechanism of Action:
Duration of Study
1 Year
Phase
2
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Asvini Kulasingham, RRT
bottom of page